<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246127</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE1206</org_study_id>
    <secondary_id>2013-000726-66</secondary_id>
    <nct_id>NCT02246127</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET</brief_title>
  <acronym>SEQTOR</acronym>
  <official_title>Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Neuroendocrine Tumor Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantar Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate which sequence of streptozotocin (STZ) based
      chemotherapy and the mammalian Target of Rapamycin (mTOR) inhibitor, everolimus, gives
      better results in terms of second Progression Free Survival (PFS) in well differentiated and
      advanced pancreatic NETs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STZ based chemotherapy, STZ-5FU, is the actual standard of care for advanced pancreatic
      Neuroendocrine tumours (pNETS) in the European Union. Everolimus has been recently approved
      for its use in advanced pNETs by the Food and Drug Administration (FDA) and in Europe by the
      European Medical Agency (EMA).

      A randomized study is needed to have a clear knowledge about the best sequence for its
      administration; this is, before or after palliative chemotherapy.

      There may or may not be any benefits from giving first each other treatment of the study.
      The information obtained from this study will help the physician improve the treatment and
      management of patients with advanced pNET.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Second Progression Free Survival (second PFS)</measure>
    <time_frame>Up to 140 +/- 8 weeks</time_frame>
    <description>PFS of Course 1 (PFS1) + interval between treatments + PFS of Course 2 (PFS2), where PFS1 represents progression free survival of Course 1 and PFS2 represents progression free survival of Course 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 30 days after 140 +/- 8 weeks</time_frame>
    <description>Number of adverse events, dose reductions, and total dose administered of each treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first progression</measure>
    <time_frame>Up to 44 weeks to everolimus and up 96 weeks for STZ-5-FU.</time_frame>
    <description>Time from the date of randomization to the date of first disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of incremental cost-efficacy (ICER)</measure>
    <time_frame>Up to 140+/-8 weeks</time_frame>
    <description>Ratio of the difference of costs incurred on by each treatment arm and the difference of second progression free survival at each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>Baseline and every 12 weeks up to 140+/-8 weeks</time_frame>
    <description>Rate of objective response (= Complete response (CR)+ Partial Response (PR)+Stable Disease (SD)) measured by RECIST criteria version 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Biochemical response</measure>
    <time_frame>Baseline and up to 4 weeks</time_frame>
    <description>Levels of Chromogranin A (CgA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second progression</measure>
    <time_frame>Up to 140+/-8 weeks</time_frame>
    <description>From the date of randomization to the date of second disease progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaire (QLQ)</measure>
    <time_frame>Prior to initial dose on day 1 and after the last dose of each treatment</time_frame>
    <description>QLQ-C30 ver 3.0 QLQ specific for gastrointestinal neuroendocrine tumors (GINET21)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 140+/-8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Pancreatic Neuroendocrine Tumours.</condition>
  <arm_group>
    <arm_group_label>Sequence A, drug: everolimus first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B, drug: STZ - 5FU first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Everolimus</intervention_name>
    <description>10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Sequence A, drug: everolimus first</arm_group_label>
    <arm_group_label>Sequence B, drug: STZ - 5FU first</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STZ-5FU</intervention_name>
    <description>0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Sequence A, drug: everolimus first</arm_group_label>
    <arm_group_label>Sequence B, drug: STZ - 5FU first</arm_group_label>
    <other_name>STZ based Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of unresectable or metastatic, advanced pancreatic
             NET.

          -  Documented confirmation of pancreatic NET G1 or G2 as per European Neuroendocrine
             Society (ENETS) classification system.

          -  Patients from whom a paraffin-embedded primary tumour or metastasis block is
             available and to be sent by Courier.

          -  Before study inclusion, patients must show progressive disease documented by
             radiology 12 months prior to study inclusion. Treatment naive patients can be also
             included if the patient needs active treatment with either chemotherapy or
             everolimus.

          -  Presence of measurable disease as per Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria 1.0, documented by a Triphasic Computed Tomography (CT) scan or
             multiphase MRI radiological assessment.

          -  Previous treatment with somatostatin (SS) analogues is allowed. Only those patients
             with active functioning syndrome at entry can continue with SS analogues during the
             study.

          -  Adequate bone marrow and renal functions, and serum fasting cholesterol

          -  Women with child-bearing potential must have a negative serum pregnancy test.

          -  Written Informed Consent obtained according to local regulations

        Exclusion Criteria:

          -  Previous treatment with chemotherapy and/or mTOR inhibitors or tyrosine kinase
             inhibitors.

          -  Immune therapy or radiation therapy within 4 weeks prior to the patient entering the
             study.

          -  Hepatic artery embolization within the last 6 months (1 month if there are other
             sites of measurable disease), or cryoablation/radiofrequency ablation of hepatic
             metastasis within 2 months of enrolment.

          -  Previous treatment with Peptide-Receptor Radionuclide Therapy (PRRT) within the last
             6 months and/or without progression following PRRT.

          -  Uncontrolled diabetes mellitus.

          -  Any severe and/or uncontrolled medical conditions.

          -  Treatment with potent inhibitors or inducers of Cytochrome P450 3A4 (CYP3A) isoenzyme
             within 5 days immediately before the start of treatment.

          -  Patients on chronic treatment with corticosteroids or any other immunosuppressive
             agent.

          -  Patients known to be HIV seropositive.

          -  Known intolerance or hypersensitivity to everolimus or its excipients or other
             rapamycin analogues. Patients with rare hereditary problems of galactose intolerance,
             Lapp lactase deficiency or glucose-galactose malabsorption should not take this
             medicinal product.

          -  Known intolerance or hypersensitivity to 5FU or STZ or its excipients (notice that
             this criterion includes patients with known deficit of dihydropyrimidine
             dehydrogenase deficiency -DPD).

          -  Pregnant, lactating women or fertile adults not using effective birth control
             methods.

          -  For administrative matters (insurance) patients ≥ 95 are not allowed during the
             trial.

        Only those patients coming from the hospital pool will be included in SEQTOR trial (e.g.
        persons detained in an institution as a result of an official or court order are
        excluded).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>94 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salazar Ramon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Catalán de Oncologia, ICO-Hospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Vidal, BSc, PhD</last_name>
    <phone>+34932134478</phone>
    <email>cvidal@meedsamdaims.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentin Navarro, BStatistics</last_name>
    <phone>:+34 93 260 78 22</phone>
    <email>vnavarro@iconcologia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Morten Ladekarl</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ulrich Peter Knigge</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lene Vestermark</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jean-Philippe Metges</name>
      <address>
        <city>Brest</city>
        <state>Brest Cedex</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philippe Ruszniewski</name>
      <address>
        <city>Clichy</city>
        <state>Clichy Cedex</state>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bernard Goichot</name>
      <address>
        <city>Strasbourg</city>
        <state>Strasbourg Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Denis Smith</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Walter</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dieter Hörsch</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joerg Schrader</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birgit Cremer</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Malfertheiner</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anja Rinke</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christoph Josef Auernhammer</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bruno Neu</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carlo Carnaghi</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salvatore Tafuto</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Klumpen</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paula Jimenez</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexander Teule</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marta Martin</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jaume Capdevila</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maria Isabel Sevilla</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marta Benavent</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbro Eriksson</name>
      <address>
        <city>Upsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 3, 2015</lastchanged_date>
  <firstreceived_date>August 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced pNET</keyword>
  <keyword>everolimus</keyword>
  <keyword>STZ-5FU</keyword>
  <keyword>treatment sequence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
